Pramipexole

Drug #1713

Pramipexole is directly acting dopamine-receptor (D-2) agonist, similar to bromocriptine. Pramipexole is used alone or as an adjunct in the treatment of parkinsonism. It also has some mood-elevating properties.

← Previous drug Next drug →

Primary Characteristics

Non-proprietary name: Pramipexole.

Pharmacokinetics

Distribution: Pramipexole has a volume of distribution is 7.3(5.6-9)l/kg. plasma protein binding is 15%.

Elimination: plasma half-life is 11.6(9.03-14.17)hr, renal excretion is ~90%.

Indications

Pramipexole is primarily indicated in conditions like Parkinson's disease.

Contraindications

Pramipexole is contraindicated in conditions like Breast feeding.

Dosage

Pramipexole's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.375 mg/day	0.375 mg/day	—	PO	Should be given in 3 divided doses, increase gradually by 0.125 mg/dose every 5-7 days. Range: 1.5-4.5 mg/day
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

9 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Pramipexole is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Dizziness, Drowsiness, Dyskinesia , Hallucination , Nausea and vomiting, Peripheral edema.

Warnings / Precautions

Pramipexole should be used with caution in patients with renal impairment (May need dose reduction); psychotic disorders; opthamological testing recommended (risk of visual disorders); severe cardiovascular disease; pregnancy (use only if potential benefit outweighs risk); avoid abrupt withdrawl (risk of neuroleptic malignant syndrome).

Available Brands

None recorded.

Drug Classification

1.9.1 — Drugs used in parkinsonism